Taro Foresees OTC Licensing Deals For Cough/Cold Pediatric Delivery System
This article was originally published in The Tan Sheet
Executive Summary
Taro Consumer Healthcare Products will consider licensing its NonSpil drug delivery system, used in the firm's ElixSure line of cough/cold medicines for children, to other over-the-counter drug manufacturers
You may also be interested in...
Taro Recovering From Profit Shortage Following Branded OTC Promotions
A steady increase in sales and lowering of costs in the second half of 2004 show Taro is recovering from profit shortages that stemmed in part from promotional spending on its branded OTC products, the firm says
Taro Sees ElixSure Licensing As Means To Building Consumer Awareness
Taro Pharmaceuticals is continuing to pursue possible licensing arrangements for its ElixSure NonSpil technology, according to CFO Kevin Connelly
Taro To Expand ElixSure Line, Posts 49% Sales Gain In 2003
Taro Pharmaceutical Industries will expand its ElixSure product line late in the second quarter with Children's ElixSure IB (ibuprofen) Oral Suspension